New data with AbbVie’s IL-23 inhibitor Skyrizi suggests it can alleviate symptoms in psoriasis patients who don’t respond well to other biologics for the skin disease, including widely-used IL ...

AbbVie’s hotly anticipated psoriasis drug Skyrizi (risankizumab) has been approved in Japan, the first country to okay this potential blockbuster. Skyrizi is important for AbbVie as sales of its ...

People taking Skyrizi in clinical trials didn’t report having depression. However, it’s important to note that plaque psoriasis and depression may have links. (Skyrizi is approved to treat ...

as compared with every 12 weeks with a drug like risankizumab [Skyrizi]," she said. "Patients really love that because they ...

relative to quarterly Skyrizi maintenance dosing,” the analysts added in a March 10 note. The clinical wins didn't end with psoriasis either. Monday morning, J&J also announced that icotrokinra ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

The three other GLP-1s on the list are Ozempic (No. 2), Wegovy (No. 8) and Zepbound (No. 10). AbbVie’s Skyrizi, a biologic approved for plaque psoriasis, psoriatic arthritis, Crohn’s disease and ...

Medscape Medical News, March 02, 2019 Alert EU Panel Backs Risankizumab (Skyrizi) for Plaque Psoriasis The interleukin-23 inhibitor is for treatment of moderate to severe plaque psoriasis in ...

Medscape Medical News, July 19, 2024 GRAPPA 2024 Psoriasis: Tissue Resident Memory ... MDedge News, June 21, 2024 Alert FDA Approves Skyrizi for Ulcerative Colitis The approval is the fourth ...